We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SGX Pharmaceuticals has discontinued the Phase II/III trial of Troxatyl as a third-line treatment for patients with acute myelogenous leukemia (AML) based on the recommendation of the study's independent data and safety monitoring board.
Allos Therapeutics has completed patient enrollment in its Phase III study of Efaproxtn (efaproxiral) in women with brain metastases originating from breast cancer.
Cellegy Pharmaceuticals has announced it plans to discontinue the Phase III trial of Savvy (C31G vaginal gel) being conducted in Nigeria to determine whether it is safe and effective for reducing women's risk of acquiring HIV.
Connetics has announced positive results of a Phase III clinical trial of Extina (ketoconazole) Foam 2 percent, formulated in VersaFoam-HF, for the treatment of seborrheic dermatitis.
Labopharm announced that its new drug submission for its extended-release formulation of tramadol has been accepted for review by the Therapeutic Products Directorate of Health Canada.
Epix Pharmaceuticals has received a letter from the FDA denying the company's formal appeal to approve its blood-pool imaging agent Vasovist (gadofosveset trisodium) and turning down its request for an advisory committee review of Vasovist.
Acuity Pharmaceuticals and Pathogenics announced publication of preclinical data demonstrating the potential clinical utility of N-Chlorotaurine (NCT) in the treatment of viral conjunctivitis.